Sobi's Long-Serving CEO Guido Oelkers to Step Down
The board has started a successor search as Oelkers stays on through January 2027 and Sobi reports 2,000 employees worldwide.
- On Monday, August 3, 2026, Swedish Orphan Biovitrum announced that CEO Guido Oelkers, Ph.D., will step down to become Chief Executive Officer of BioNTech SE, transitioning by February 1, 2027.
- Oelkers has led Sobi since 2017, quadrupling revenues to SEK 28 billion while strengthening the rare disease portfolio; he will remain active in his CEO role until end of January 2027.
- Sobi Chairman David Meek thanked Oelkers for "nearly 10 years of dedication and leadership," while Oelkers said, "Leading Sobi has been a privilege, and I am proud of what we have accomplished together as a team."
- The Sobi Board of Directors has begun identifying a successor to ensure what Meek called "continuity and a smooth transition for our business and our employees." Operations and financial targets remain unchanged.
- Succeeding Prof. Ugur Sahin, M.D., Oelkers joins BioNTech's Management Board to support the company's strategy to become a multi-product firm in the competitive mRNA sector.
21 Articles
21 Articles
The pharmaceutical manager Guido Oelkers is due to lead the vaccine manufacturer Biontech from next year.
In the Corona pandemic, Biontech becomes one of the biopharma addresses in Germany. The Mainz-based company, however, is most recently in a state of crisis. A new boss could give an impulse. Guido Oelkers has now found it, which is primarily intended to boost the US business.
BioNTech has announced the appointment of Guido Oelkers, current head of Swedish Orphan Biovitrum (Sobi), to replace co-founder Ugur Sahin as its next CEO. Exclusive content for subscribers. For full access, follow the link to the article and register.
It is not yet clear which development the vaccine specialist Biontech is taking after the departure of its founders. After all, it is now clear who follows Ugur Şahin on the head chair.
Guido Oelkers succeeds BioNTech founder Uğur Şahin, who wants to leave the vaccine manufacturer together with co-founder Özlem Türeci by the end of 2026.
Coverage Details
Bias Distribution
- 46% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
